Jefferies Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $145
Glaukos IDose: Transforming Glaucoma Treatment With Promising Growth Potential
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
Glaukos Eyes FDA Approval for Ocular Therapy After Phase III Win
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $145
Stifel Nicolaus Issues a Buy Rating on Glaukos (GKOS)
Wells Fargo Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $135
Piper Sandler Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $140
Piper Sandler Remains a Buy on Glaukos (GKOS)
Glaukos Receives Buy Rating Amidst Promising Phase 3 Epioxa Trial Results and Growth Prospects
Glaukos Reports Positive Results From Potential Eye Disease Treatment Study
Express News | Glaukos Corp - Phase 3 Trial Supports Nda Submission by End of 2024
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa , Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
Express News | Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
Ripple Therapeutics Announces Evaluation and Licensing Agreements With Glaukos
A Closer Look at 7 Analyst Recommendations For Glaukos
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $152
Glaukos Is Maintained at Buy by Truist Securities
Glaukos Analyst Ratings